<DOC>
	<DOCNO>NCT01065623</DOCNO>
	<brief_summary>Clinical study determine safety , tolerability , measure drug metabolize body determine maximum tolerate dose BAY79-4620 give every 2 week patient advance solid tumor</brief_summary>
	<brief_title>Clinical Study Evaluate Maximum Tolerated Dose BAY79-4620 Given Every 2 Weeks Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The informed consent must sign study specific test procedures do Male female patient age &gt; 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy least 12 week Patients advance , histologically cytologically confirm solid tumor , refractory standard therapy , standard therapy available , patient must actively refuse treatment would regard standard , and/or judgment investigator designate associate ( ) , experimental treatment clinically ethically acceptable Radiographically clinically evaluable tumor Adequate bone marrow , liver , renal function assess follow laboratory requirement conduct within 14 day prior start first dose History cardiac disease : congestive heart failure ( CHF ) &gt; NYHA Class II ; myocardial infarction within 3 month prior study entry ; new onset angina within 3 month unstable angina cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Uncontrolled hypertension define systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 95 mmHg , despite optimal medical management Symptomatic metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , evidence tumor growth image study within 2 week prior study entry , clinically stable respect tumor time study entry . Patients severe renal impairment dialysis Known human immunodeficiency virus ( HIV ) infection patient active hepatitis B C infection necessitate treatment . Patients chronic hepatitis B C eligible Active clinically serious infection Common Terminology Criteria Adverse Events Version 3 ( CTCAE v3.0 ) &gt; Grade 2 Serious , nonhealing wound , ulcer , bone fracture Major surgery , open biopsy , significant trauma within 4 week prior first dose study drug Anticancer chemotherapy , experimental cancer therapy , immunotherapy within 2 week start first dose Radiotherapy target lesion within 3 week prior Cycle 1 Day 1 ( first dose study drug ) . Palliative radiotherapy allow describe study protocol . Radiotherapy target lesion study regard progressive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Immunoconjugate</keyword>
</DOC>